about
Cytokine production associated with smallpox vaccine responsesThe effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model dataStructural and Biochemical Characterization of the Vaccinia Virus Envelope Protein D8 and Its Recognition by the Antibody LA5Potent Neutralization of Vaccinia Virus by Divergent Murine Antibodies Targeting a Common Site of Vulnerability in L1 ProteinBiodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes TargetingEPIPOX: Immunoinformatic Characterization of the Shared T-Cell Epitome between Variola Virus and Related Pathogenic OrthopoxvirusesReview: Capripoxvirus Diseases: Current Status and Opportunities for Control.Host responses in human skin after conventional intradermal injection or microneedle administration of virus-like-particle influenza vaccine.Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.Genes in the terminal regions of orthopoxvirus genomes experience adaptive molecular evolutionNonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesProtection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies.Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model.B cell-specific expression of B7-2 is required for follicular Th cell function in response to vaccinia virus.CD4+ T cell help is dispensable for protective CD8+ T cell memory against mousepox virus following vaccinia virus immunization.Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges.Disabling complement regulatory activities of vaccinia virus complement control protein reduces vaccinia virus pathogenicity.Murine anti-vaccinia virus D8 antibodies target different epitopes and differ in their ability to block D8 binding to CS-EEnhancement of CD8(+) T-cell memory by removal of a vaccinia virus nuclear factor-κB inhibitor.Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAsRecombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.Failure of the smallpox vaccine to develop a skin lesion in vaccinia virus-naïve individuals is related to differences in antibody profiles before vaccination, not after.Whither monkeypox vaccinationThe DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice.Serological responses in humans to the smallpox vaccine LC16m8.Characterization of hepatitis E virus recombinant ORF2 proteins expressed by vaccinia viruses.Genetic Variability of Myxoma Virus Genomes.Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian Smallpox Vaccine Strain IOC: Implications for the Origins and Evolutionary Relationships of Vaccinia VirusPoxviral vectors for cancer immunotherapyUnusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine.L1R, A27L, A33R and B5R vaccinia virus genes expressed by fowlpox recombinants as putative novel orthopoxvirus vaccinesOX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory virusesRespiratory syncytial virus: current progress in vaccine development.Complex correlates of protection after vaccination.Species Specificity of Vaccinia Virus Complement Control Protein for the Bovine Classical Pathway Is Governed Primarily by Direct Interaction of Its Acidic Residues with Factor I.Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo.OX40 Cooperates with ICOS To Amplify Follicular Th Cell Development and Germinal Center Reactions during Infection.Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus InfectionsEliciting Epitope-Specific CD8+ T Cell Response by Immunization with Microbial Protein Antigens Formulated with α-Galactosylceramide: Theory, Practice, and Protocols.
P2860
Q26823501-4DB8C85F-4AEA-4A5B-AAA6-03492B4392C8Q26996686-79D3B183-0A98-4AE6-9592-B73857A7C657Q27679281-7B7569CA-7913-4EC6-A71C-C19F576A9BB1Q27684713-68571F42-1E22-40BD-B6B5-4D1E71FDCE65Q28072997-C513B841-1872-4EB3-B138-0E5AF186F58EQ28607584-1A0A8B4C-AD2A-4C21-9070-557E7E2455D9Q30252040-213BC2D2-9B32-45BB-AF12-B8846B1F0E05Q33563977-4E4E6B08-248F-47A6-BBAC-F8FF056AAFFAQ33743444-D4FCC161-C26F-43E1-984B-6C1D4D33D204Q33909381-165945C5-30F7-4DD3-AF1B-92CC833D14B9Q34057711-4C05841A-A0C4-43CD-898E-BB92B9C22BF6Q34469836-4E03D289-92CF-4885-88E6-C385BD5F5588Q34779016-8564F5F6-4CEA-4F09-96F6-186ACD7CD1EBQ34950531-8F7BDD85-14ED-4F27-944C-58FCAEC96407Q34992708-AE426692-B2CD-4FEB-AE3D-8C6C9FDCC06FQ35076706-0B334AD8-B898-41AB-A310-8DC7EB12A668Q35140284-0097F601-0E11-47CE-981E-051EDD1E67B6Q35367093-0DEAD30B-8856-4CCD-B584-83E34A8228AAQ35489874-ABEF3436-CED1-4A08-A1B7-8EF457EF90F4Q35512353-18C8C77F-2341-49F2-926B-70B08F2E90F5Q35634159-5C35ACBB-8276-4839-A6E3-96432BE4182EQ35677112-438BE532-849A-45CD-A7DE-63607E5FF4D5Q35805278-5BC677BB-F884-4DBE-BE4E-EF4D583C68D3Q35850790-EEF6B009-2B3D-44A3-814E-5F1D9987E22DQ35913709-15AA8976-D352-4831-8FC4-F9F78D016511Q35945094-90B0CEE2-E30E-491A-8A71-F9E1E597E63BQ36171812-9FA7F8BA-544B-40DF-AEFE-DE6A45E0DD36Q36208692-55D3E741-EC7A-4104-9B4C-9DD9871B02C6Q36281104-7BCD1B03-547A-40E8-A672-7DCC2EB97AE9Q36350388-2CE0EE93-7239-4C84-B456-60D72B2FAB07Q36559797-D83AE018-8B9B-49C6-A6AE-0CE6A7748610Q36798711-9D5EA326-12B7-4E42-8DBE-B39F48583DC6Q37948126-4D9AC303-11CE-47EA-AFAF-2D577D1D57DDQ38079432-A17C6597-8DBC-4906-B30F-042E3B413485Q38456515-588A0422-4F19-45D3-BF8B-61584B548F61Q38671434-F0B8BDC1-EC61-4369-83F0-B6CCCE256B09Q39320211-FD87B74C-F423-47DE-8FD9-025A1C09AB48Q40432376-D989DC57-6B24-444A-9EDB-2DD72057890AQ40494092-09E6328E-A85F-4E79-982A-BD43E543C6DBQ40513167-98C27E50-5D6E-4098-B717-0A783649FA9D
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Smallpox vaccines: targets of protective immunity.
@ast
Smallpox vaccines: targets of protective immunity.
@en
Smallpox vaccines: targets of protective immunity.
@nl
type
label
Smallpox vaccines: targets of protective immunity.
@ast
Smallpox vaccines: targets of protective immunity.
@en
Smallpox vaccines: targets of protective immunity.
@nl
prefLabel
Smallpox vaccines: targets of protective immunity.
@ast
Smallpox vaccines: targets of protective immunity.
@en
Smallpox vaccines: targets of protective immunity.
@nl
P2860
P1476
Smallpox vaccines: targets of protective immunity.
@en
P2860
P356
10.1111/J.1600-065X.2010.00975.X
P50
P577
2011-01-01T00:00:00Z